Story · Medicine & Biotech

Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical

1 outlet · first reported by GEN Genetic Engineering News 7d ago

Coverage, in order

  1. 7d ago
    GEN Genetic Engineering News indie
    Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical

    Boehringer Ingelheim has launched an up-to-$7.358 billion-plus second collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. The companies have signed a strategic multi-program…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.